Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Buprenorphine PK for OUD Induction
NCT06086275Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of buprenorphine extended-release injection in opioid use disorder (OUD) (3 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Plasma-Concentration Curves (AUC) of Buprenorphine at 24 hours. Started Jun 2024; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06086275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086275.